Nifty Labs by Coinsilium Group Limited’s Begins NFT on Bitcoin Marketplace Powered by RSK Development
6 hours ago by Kseniia Klichova · 8 min read
Photo: Depositphotos
You have successfully joined our subscriber list.
A gallery, an NFT minter, and other modules are expected to be built for the newly announced platform.
Coinsilium Group Limited is a crypto and open finance project building platform that develops and deploys blockchain-based products and services. It was the first blockchain company to go public in 2015. Using its experience and wide network, it has invested in successful and leading blockchain ventures such as RSK/IOV Labs, Blox, Indorse, etcetera. Coinsilium’s shares are now traded on the OTCQB Venture Market in New York and the AQSE Growth Market in London under the ticker symbols “CINGF” and “COIN,” respectively.
“W
e want to be able to stretch those dollars as much as possible, because, at this point we have no idea the depth and magnitude of the needs were going to have in helping students address the challenges that are going to come out of Covid.”
He says $10,494,081 will go into the budget that starts July 1 this year. Another $8,125,827.16 will be used the following year.
“
We’ll end up using some of CARES III, or the ARPA funds, next year. But the lion’s share will be utilized in FY 23, and possibly a little bit in FY 24.”
This federal COVID relief was signed into law on March 11. The ARP Act provides an additional $122 billion for puts money into the Elementary and Secondary School Emergency Relief Fund, or what’s called the ESSER Fund.
Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca Proteros to receive research funding and milestone payments plus royalties
Proteros biostructures GmbH ( Proteros ) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.
The collaboration brings together Proteros discovery capabilities which are tailored to unlock even the most technically challenging drug targets with AstraZeneca s expertise in target biology and medicinal chemistry to jointly discover novel lead compounds which will be further developed, manufactured, and commercialized by AstraZeneca.
Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.
Второе вторжение России на Украину неизбежно? chechenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chechenews.com Daily Mail and Mail on Sunday newspapers.